Page last updated: 2024-11-07

dextroamphetamine and Chronic Disease

dextroamphetamine has been researched along with Chronic Disease in 24 studies

Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To evaluate the efficacy of intratarsal triamcinolone acetonide (TA) injection versus dexamethasone ointment in the treatment of refractory chronic tropical endemic limboconjunctivitis (TELC)."9.16[Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar]. ( Ba, EH; Ka, AM; Ndiaye, MR; Ndoye Roth, PA; Ngatcho Hemo, J; Sow, AS; Wade, A; Wane Khouma, AM, 2012)
"Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0."9.07Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991)
"To present two other dermatologic conditions related to a disorder of sympathetic nervous system hypofunction common in women that respond to treatment with dextroamphetamine sulfate--chronic eczema and keratosis pilaris."7.80Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate. ( Chan, S; Check, JH, 2014)
"To evaluate the efficacy of intratarsal triamcinolone acetonide (TA) injection versus dexamethasone ointment in the treatment of refractory chronic tropical endemic limboconjunctivitis (TELC)."5.16[Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar]. ( Ba, EH; Ka, AM; Ndiaye, MR; Ndoye Roth, PA; Ngatcho Hemo, J; Sow, AS; Wade, A; Wane Khouma, AM, 2012)
"Twenty-one patients with chronic schizophrenia who were hospitalized on a research ward received a single oral dose of dextroamphetamine (0."5.07Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. ( Bigelow, LB; Daniel, DG; Goldberg, TE; Kleinman, JE; Weinberger, DR, 1991)
"Dextroamphetamine sulfate 15-mg extended release capsules were given to women with a variety of treatment refractory conditions including, but not limited to, pelvic pain."3.81Sympathomimetic amines are a safe, highly effective therapy for several female chronic disorders that do not respond well to conventional therapy. ( Check, JH, 2015)
"To present two other dermatologic conditions related to a disorder of sympathetic nervous system hypofunction common in women that respond to treatment with dextroamphetamine sulfate--chronic eczema and keratosis pilaris."3.80Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate. ( Chan, S; Check, JH, 2014)
"To determine if a very effective therapy for idiopathic orthostatic cyclic edema--dextroamphetamine sulfate--would alleviate symptoms of chonic pelvic pain of bladder origin/interstitial cystitis."3.73A novel highly effective treatment of interstitial cystitis causing chronic pelvic pain of bladder origin: case reports. ( Bonnes, E; Check, JH; Citerone, T; Katsoff, B, 2005)
" The medication trials were double-blind, placebo-controlled, dose-response studies."2.66Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. ( Evans, RW; Gualtieri, CT; Patterson, D, 1987)
"Dextroamphetamine sulfate was initiated at 15 mg extended release capsules increasing to 25 mg extended release capsules to a 47-year-old woman."1.42Complete resolution of frozen shoulder syndrome in a woman treated with dextroamphetamine sulfate for chronic urinary urgency. ( Check, JH; Cohen, R, 2015)
"Dextroamphetamine sulfate was prescribed."1.40Sympathomimetic amine therapy found effective for treatment of refractory chronic complex regional pain syndrome (reflex sympathetic dystrophy). ( Check, JH; Cohen, R, 2014)
" Personal or family tic history, medication selection, or dosage was not related to onset of T/D."1.29Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. ( Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994)
"The daytime somnolence was confirmed objectively by polygraphic monitoring seven weeks to 4 1/2 months after the onset of clinical symptoms."1.27Mononucleosis and chronic daytime sleepiness. A long-term follow-up study. ( Guilleminault, C; Mondini, S, 1986)

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19909 (37.50)18.7374
1990's3 (12.50)18.2507
2000's4 (16.67)29.6817
2010's8 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Check, JH8
Chan, S1
Cohen, R3
Chiu, HF1
Cheng, JK1
Lin, PH1
Chang, JC1
Chen, IM1
Lin, CI1
Chang, WP1
Lin, CH1
Nuijten, M1
Blanken, P1
van de Wetering, B1
Nuijen, B1
van den Brink, W1
Hendriks, VM1
Check, D1
Ndoye Roth, PA1
Ngatcho Hemo, J1
Wane Khouma, AM1
Ba, EH1
Sow, AS1
Ka, AM1
Ndiaye, MR1
Wade, A1
Katsoff, B1
Citerone, T1
Bonnes, E1
Amadi, C1
Kaplan, H1
Katsoff, D1
Whiting, E1
Chenery, HJ1
Chalk, J1
Copland, DA1
Gentlesk, MJ1
Falanga, V1
Wince, LC1
Donovan, CA1
Azzaro, AJ1
Lipkin, PH1
Goldstein, IJ1
Adesman, AR1
Gambarana, C1
Masi, F1
Tagliamonte, A1
Scheggi, S1
Ghiglieri, O1
De Montis, MG1
Vekovischeva, OY1
Zamanillo, D1
Echenko, O1
Seppälä, T1
Uusi-Oukari, M1
Honkanen, A1
Seeburg, PH1
Sprengel, R1
Korpi, ER1
Goode, DJ1
Meltzer, HY2
Mazura, TA1
Reches, A1
Ebstein, RP1
Belmaker, RH1
Kornetsky, C1
Goldberg, TE1
Bigelow, LB1
Weinberger, DR1
Daniel, DG1
Kleinman, JE1
Sommers, AA1
Luchins, DJ1
Evans, RW1
Gualtieri, CT1
Patterson, D1
Guilleminault, C1
Mondini, S1
Rappaport, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study[NCT05529927]Phase 2204 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

Trials

7 trials available for dextroamphetamine and Chronic Disease

ArticleYear
Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2016, May-28, Volume: 387, Issue:10034

    Topics: Administration, Oral; Central Nervous System Stimulants; Chronic Disease; Cocaine-Related Disorders;

2016
[Intratarsal triamcinolone acetonide injection for treatment of refractory chronic tropical endemic limboconjunctivitis (TELC): experience at Aristide-Le-Dantec university hospital in Dakar].
    Journal francais d'ophtalmologie, 2012, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Chronic Disease; Conjunctiviti

2012
Dexamphetamine boosts naming treatment effects in chronic aphasia.
    Journal of the International Neuropsychological Society : JINS, 2007, Volume: 13, Issue:6

    Topics: Aged; Aphasia; Blood Pressure; Central Nervous System Stimulants; Chronic Disease; Dextroamphetamine

2007
Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine.
    Archives of general psychiatry, 1976, Volume: 33, Issue:12

    Topics: Adult; Behavior; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dopam

1976
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
    The American journal of psychiatry, 1991, Volume: 148, Issue:1

    Topics: Adult; Affect; Blinking; Cerebral Ventricles; Chronic Disease; Cognition; Concept Formation; Dextroa

1991
The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:6

    Topics: Alprazolam; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Dextroamphetamine; Dose

1986
Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure.
    The Journal of nervous and mental disease, 1987, Volume: 175, Issue:2

    Topics: Adult; Attention; Chronic Disease; Clinical Trials as Topic; Cognition Disorders; Craniocerebral Tra

1987

Other Studies

17 other studies available for dextroamphetamine and Chronic Disease

ArticleYear
Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate.
    Clinical and experimental obstetrics & gynecology, 2014, Volume: 41, Issue:2

    Topics: Abnormalities, Multiple; Chronic Disease; Darier Disease; Dextroamphetamine; Eczema; Eyebrows; Fatig

2014
Sympathomimetic amine therapy found effective for treatment of refractory chronic complex regional pain syndrome (reflex sympathetic dystrophy).
    Clinical and experimental obstetrics & gynecology, 2014, Volume: 41, Issue:4

    Topics: Acupuncture Analgesia; Adult; Central Nervous System Stimulants; Chronic Disease; Dextroamphetamine;

2014
A mechanistic study on urine retention in d-amphetamine addicts.
    The Chinese journal of physiology, 2014, Aug-31, Volume: 57, Issue:4

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Afferent Pathways; Amidines; Amphetamine-Related Disorders; An

2014
Sympathomimetic amines are a safe, highly effective therapy for several female chronic disorders that do not respond well to conventional therapy.
    Clinical and experimental obstetrics & gynecology, 2015, Volume: 42, Issue:3

    Topics: Central Nervous System Stimulants; Chronic Disease; Cystitis, Interstitial; Dextroamphetamine; Fatig

2015
Complete resolution of frozen shoulder syndrome in a woman treated with dextroamphetamine sulfate for chronic urinary urgency.
    Clinical and experimental obstetrics & gynecology, 2015, Volume: 42, Issue:5

    Topics: Bursitis; Chronic Disease; Dextroamphetamine; Female; Humans; Middle Aged; Sympathomimetics; Urinary

2015
Idiopathic edema, a condition associated with pelvic pain and other symptoms in women, as a remedial cause of chronic cold induced urticaria.
    Clinical and experimental obstetrics & gynecology, 2010, Volume: 37, Issue:3

    Topics: Adolescent; Chronic Disease; Cold Temperature; Dextroamphetamine; Drug Resistance; Edema; Female; Hu

2010
A novel highly effective treatment of interstitial cystitis causing chronic pelvic pain of bladder origin: case reports.
    Clinical and experimental obstetrics & gynecology, 2005, Volume: 32, Issue:4

    Topics: Adult; Chronic Disease; Cystitis, Interstitial; Dextroamphetamine; Female; Humans; Pelvic Pain; Symp

2005
The treatment of idiopathic edema, a cause of chronic pelvic pain in women: effectively controlled chronic refractory urticaria--case reports.
    Clinical and experimental obstetrics & gynecology, 2006, Volume: 33, Issue:3

    Topics: Chronic Disease; Dextroamphetamine; Diagnosis, Differential; Edema; Female; Humans; Pelvic Pain; Ret

2006
Sympathomimetic amines in the treatment of chronic urticaria: two case reports.
    Cutis, 1984, Volume: 34, Issue:4

    Topics: Adult; Chronic Disease; Dextroamphetamine; Edema; Female; Humans; Obesity; Posture; Urticaria

1984
Alterations in the biochemical properties of central dopamine synapses following chronic postnatal PbCO3 exposure.
    The Journal of pharmacology and experimental therapeutics, 1980, Volume: 214, Issue:3

    Topics: Animals; Brain; Chronic Disease; Dextroamphetamine; Dopamine; Lead Poisoning; Motor Activity; Potass

1980
Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.
    Archives of pediatrics & adolescent medicine, 1994, Volume: 148, Issue:8

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Chronic Disease;

1994
A chronic stress that impairs reactivity in rats also decreases dopaminergic transmission in the nucleus accumbens: a microdialysis study.
    Journal of neurochemistry, 1999, Volume: 72, Issue:5

    Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Chronic Disease; Cocaine; Dextroamphetamine

1999
Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, Jun-15, Volume: 21, Issue:12

    Topics: Acute Disease; Animals; Behavior, Animal; Brain; Calcium; Chronic Disease; Dextroamphetamine; Diseas

2001
Hoffmann reflex abnormalities in psychotic patients.
    Biological psychiatry, 1979, Volume: 14, Issue:1

    Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dextr

1979
d-amphetamine inhibition of platelet MAO from schizophrenic patients.
    Biological psychiatry, 1977, Volume: 12, Issue:5

    Topics: Adult; Aged; Animals; Blood Platelets; Chronic Disease; Dextroamphetamine; Female; Haplorhini; Human

1977
Mononucleosis and chronic daytime sleepiness. A long-term follow-up study.
    Archives of internal medicine, 1986, Volume: 146, Issue:7

    Topics: Adolescent; Adult; Chronic Disease; Circadian Rhythm; Dextroamphetamine; Disorders of Excessive Somn

1986
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background.
    The Journal of nervous and mental disease, 1968, Volume: 146, Issue:5

    Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta

1968